AR071245A1 - Derivados de piperidina como antagonistas de receptores muscarinicos, procesos de obtencion y composiciones farmaceuticas - Google Patents
Derivados de piperidina como antagonistas de receptores muscarinicos, procesos de obtencion y composiciones farmaceuticasInfo
- Publication number
- AR071245A1 AR071245A1 ARP080103926A ARP080103926A AR071245A1 AR 071245 A1 AR071245 A1 AR 071245A1 AR P080103926 A ARP080103926 A AR P080103926A AR P080103926 A ARP080103926 A AR P080103926A AR 071245 A1 AR071245 A1 AR 071245A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- heterocycloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de piperidina, así como también se preparan sales y composiciones farmacéuticas que incluyen los compuestos. Son utiles en la terapia, en particular en el tratamiento del dolor. Reivindicacion 1: Un compuesto de la formula (1), una sal farmacéuticamente aceptable del mismo, diastereomero, enantiomero, o una mezcla de los mismos, donde R2 se selecciona de hidrogeno, cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, alqueniloxi C2-6, alquiniloxi C2-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, arilo C6-10-alcoxi C1-3, arilo C6-10-alquilo C1-3, heteroarilo C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquilo C3-7-alcoxi C1-3, heterocicloalquilo C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquilo C3-7-alquilo C1-3 y cicloalquilo C3-7-alcoxi C1-3, donde dichos cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, alqueniloxi C2-6, alquiniloxi C2-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, arilo C6-10-alcoxi C1-3, arilo C6-10-alquilo C1-3, heteroarilo C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquilo C3-7-alcoxi C1-3, heterocicloalquilo C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquilo C3-7-alquilo C1-3 y cicloalquilo C3-7-alcoxi C1-3 están opcionalmente sustituidos con uno o más grupos seleccionados de fenilo, cicloalquilo C3-6, heterocicloalquilo C2-5, heteroarilo C3-5, -CN, -SR, -OR, -O(CH2)p-OR, R, -C(=O)-R, -CO2R, -SO2R, -SO2NRR', halogeno, -NO2, -NRR', -(CH2)p-NRR' y -C(=O)-NRR'; R3 se selecciona de alquilo C1-6 y alquilo C1-6 halogenado; p es 1, 2, 3 o 4; m y n son independientemente 1, 2, 3 o 4; X se selecciona independientemente de NH, N-R, CH2, CHR y CRR'; y cada R, R' es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6 o alquilo C1-6 halogenado; con la condicion de que dicho compuesto no se seleccione de: 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahidro-3H-benzoimidazol-1-il]-1-piperidil]-4-etil-piperidin-1-carboxilato de etilo; (3aS,7aS)-1-[1-[1-(ciclopropancarbonil)-4-propil-4-piperidil]-4-piperidil]-3a,4,5,6,7,7a-hexahidro-3H-benzoimidazol-2-ona; 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahidro-3H-benzoimidazol-1-il]-1-piperidil]-4-metil-piperidin-1-carboxilato de ter-butilo; 4-[4-[(3aR,7aR)-2-oxo-3a,4,5,6,7,7a-hexahidro-3H-benzoimidazol-1-il]-1-piperidil]-4-metil-piperidin-1-carboxilato de ter-butilo; 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahidro-3H-benzoimidazol-1-il]-1-piperidil]-4-etil-piperidin-1-carboxilato de propan-2-ilo; 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahidro-3H-benzoimidazol-1-il]-1-piperidil]-4-propil-piperidin-1-carboxilato de propan-2-ilo; y 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahidro-3H-benzoimidazol-1-il]-1-piperidil]-4-propil-piperidin-1-carboxilato de etilo. Reivindicacion 27: Un compuesto de la formula (2), una sal farmacéuticamente aceptable del mismo, diastereomero, enantiomero o una mezcla de los mismos, donde n es 1, 2, 3 o 4; m es 1, 2, 3 o 4; R3 se selecciona de alquilo C1-6 y alquilo C1-6 halogenado; X se selecciona independientemente de NH, N-R, CH2, CHR y CRR'; y cada R, R' es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6 o alquilo C1-6 halogenado. Reivindicacion 28: Un proceso para la preparacion de un compuesto de formula (3), que comprende: a) hacer reaccionar un compuesto de la formula (4) con ciclohexano-1,2-diamina para formar un compuesto de la formula (5); b) hacer reaccionar el compuesto de la formula (5) con un compuesto tipo fosgeno al compuesto de la formula (3); donde R2 se selecciona de hidrogeno, cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, alqueniloxi C2-6, alquiniloxi C2-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, arilo C6-10-alcoxi C1-3, arilo C6-10-alquilo C1-3, heteroarilo C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquilo C3-7-alcoxi C1-3, heterocicloalquilo C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquilo C3-7-alquilo C1-3 y cicloalquilo C3-7-alcoxi C1-3, donde dichos cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, alqueniloxi C2-6, alquiniloxi C2-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, arilo C6-10-alcoxi C1-3, arilo C6-10-alquilo C1-3, heteroarilo C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquilo C3-7-alcoxi C1-3, heterocicloalquilo C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquilo C3-7-alquilo C1-3 y cicloalquilo C3-7-alcoxi C1-3 están opcionalmente sustituidos con uno o más grupos seleccionados de fenilo, cicloalquilo C3-6, heterocicloalquilo C2-5, heteroarilo C3-5, -CN, -SR, -OR, -O(CH2)p-OR, R, -C(=O)-R, -CO2R, -SO2R, -SO2NRR', halogeno, -NO2, -NRR', -(CH2)p-NRR' y -C(=O)-NRR'; R3 se selecciona de alquilo C1-6 y alquilo C1-6 halogenado; p es 1, 2, 3 o 4; m y n son independientemente 1, 2, 3 o 4; y cada R, R' es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6 o alquilo C1-6 halogenado. Reivindicacion 29: Un compuesto de la formula (5), una sal farmacéuticamente aceptable del mismo, diastereomero, enantiomero o una mezcla de los mismos, donde R2 se selecciona de hidrogeno, cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, alqueniloxi C2-6, alquiniloxi C2-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, arilo C6-10-alcoxi C1-3, arilo C6-10-alquilo C1-3, heteroarilo C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquilo C3-7-alcoxi C1-3, heterocicloalquilo C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquilo C3-7-alquilo C1-3 y cicloalquilo C3-7-alcoxi C1-3, donde dichos cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, alqueniloxi C2-6, alquiniloxi C2-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, arilo C6-10-alcoxi C1-3, arilo C6-10-alquilo C1-3, heteroarilo C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquilo C3-7-alcoxi C1-3, heterocicloalquilo C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquilo C3-7-alquilo C1-3 y cicloalquilo C3-7-alcoxi C1-3 están opcionalmente sustituidos con uno o más grupos seleccionados de fenilo, cicloalquilo C3-6, heterocicloalquilo C2-5, heteroarilo C3-5, -CN, -SR, -OR, -O(CH2)p-OR, R, -C(=O)-R, -CO2R, -SO2R, -SO2NRR', halogeno, -NO2, -NRR', -(CH2)p-NRR' y -C(=O)-NRR'; R3 se selecciona de alquilo C1-6 y alquilo C1-6 halogenado; p es 1, 2, 3 o 4; n es 1, 2, 3 o 4; y cada R, R' es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6 o alquilo C1-6 halogenado. Reivindicacion 30: Un compuesto de la formula (4), una sal farmacéuticamente aceptable del mismo, diastereomero, enantiomero o una mezcla de los mismos, donde R2 se selecciona de hidrogeno, cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, alqueniloxi C2-6, alquiniloxi C2-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, arilo C6-10-alcoxi C1-3, arilo C6-10-alquilo C1-3, heteroarilo C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquilo C3-7-alcoxi C1-3, heterocicloalquilo C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquilo C3-7-alquilo C1-3 y cicloalquilo C3-7-alcoxi C1-3, donde dichos cicloalquilo C3-7, alquilo C1-7, alquenilo C2-6, alquinilo C2-6, alcoxi C1-7, alqueniloxi C2-6, alquiniloxi C2-6, alquilamino C1-6, di-alquilamino C1-6, heterocicloalquiloxi C3-7, heterocicloalquilo C3-7, arilo C6-10-alcoxi C1-3, arilo C6-10-alquilo C1-3, heteroarilo C3-9-alcoxi C1-3, heteroaril C3-9-alquilo C1-3, heterocicloalquilo C3-7-alcoxi C1-3, heterocicloalquilo C3-7-alquilo C1-3, cicloalquiloxi C3-7, cicloalquilo C3-7-alquilo C1-3 y cicloalquilo C3-7-alcoxi C1-3 están opcionalmente sustituidos con uno o más grupos seleccionados de fenilo, cicloalquilo C3-6, heterocicloalquilo C2-5, heteroarilo C3-5, -CN, -SR, -OR, -O(CH2)p-OR, R, -C(=O)-R, -CO2R, -SO2R, -SO2NRR', halogeno, -NO2, -NRR', -(CH2)p-NRR' y -C(=O)-NRR'; R3 se selecciona de alquilo C1-6 y alquilo C1-6 halogenado; p es 1, 2, 3 o 4; n es 1, 2, 3 o 4; y cada R, R' es independientemente hidrogeno, alquilo C1-6, alquenilo C2-6 o alquilo C1-6 halogenado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97128807P | 2007-09-11 | 2007-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071245A1 true AR071245A1 (es) | 2010-06-09 |
Family
ID=40011174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103926A AR071245A1 (es) | 2007-09-11 | 2008-09-10 | Derivados de piperidina como antagonistas de receptores muscarinicos, procesos de obtencion y composiciones farmaceuticas |
Country Status (18)
Country | Link |
---|---|
US (1) | US8119661B2 (es) |
EP (1) | EP2197843B1 (es) |
JP (1) | JP2010539151A (es) |
KR (1) | KR20100052528A (es) |
CN (1) | CN101874020B (es) |
AR (1) | AR071245A1 (es) |
AT (1) | ATE539056T1 (es) |
AU (1) | AU2008299604A1 (es) |
BR (1) | BRPI0816331A2 (es) |
CA (1) | CA2699286A1 (es) |
CL (1) | CL2008002689A1 (es) |
ES (1) | ES2377772T3 (es) |
MX (1) | MX2010002584A (es) |
PE (1) | PE20091090A1 (es) |
RU (1) | RU2010110036A (es) |
TW (1) | TW200924766A (es) |
UY (1) | UY31334A1 (es) |
WO (1) | WO2009034380A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
TW200815405A (en) * | 2006-06-09 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
US20090221642A1 (en) * | 2008-03-03 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176 |
US20090275574A1 (en) * | 2008-05-05 | 2009-11-05 | Astrazeneca Ab | Novel compounds-300 |
PL2780015T3 (pl) | 2011-11-18 | 2017-06-30 | Heptares Therapeutics Limited | Agonisty receptora muskarynowego M1 |
SG11201501620QA (en) | 2012-09-18 | 2015-04-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor agonists |
WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
GB2519470A (en) * | 2013-09-18 | 2015-04-22 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic M1 receptor agonists |
SG11201606269WA (en) * | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0029707B1 (en) | 1979-11-21 | 1984-02-01 | Kyowa Hakko Kogyo Co., Ltd | Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them |
DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
ATE216580T1 (de) | 1993-07-16 | 2002-05-15 | Merck & Co Inc | Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten |
WO1996013262A1 (en) | 1994-10-27 | 1996-05-09 | Merck & Co., Inc. | Muscarine antagonists |
US5756508A (en) | 1995-10-31 | 1998-05-26 | Merck & Co., Inc. | Muscarine antagonists |
WO1997016192A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
US5756497A (en) | 1996-03-01 | 1998-05-26 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
NZ334543A (en) | 1996-09-10 | 2000-06-23 | Thomae Gmbh Dr K | Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays |
JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患(gvhd)の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
WO1999032481A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
WO1999036421A1 (en) | 1998-01-19 | 1999-07-22 | Pfizer Pharmaceuticals Inc. | 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists |
MA26659A1 (fr) | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
JP2000323278A (ja) | 1999-05-14 | 2000-11-24 | Toray Ind Inc | 発光素子 |
US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
MXPA03001422A (es) | 2000-08-14 | 2004-01-26 | Johnson & Johnson | Pirazoles substituidos. |
JP2002302675A (ja) | 2001-04-06 | 2002-10-18 | Fuji Photo Film Co Ltd | 液晶組成物、それを用いた液晶素子およびアゾ化合物 |
DE60229224D1 (de) | 2001-04-18 | 2008-11-20 | Euro Celtique Sa | Nociceptin-analoga |
JP4401076B2 (ja) * | 2001-04-18 | 2010-01-20 | ユーロ−セルティーク エス.エイ. | ベンズイミダゾロン化合物 |
JPWO2002085890A1 (ja) | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
AR036366A1 (es) * | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
EP1451173A4 (en) | 2001-11-01 | 2005-10-26 | Icagen Inc | PIPERIDINE |
EP1499316B1 (en) | 2002-04-18 | 2008-03-19 | Schering Corporation | (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists |
CA2488845A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Opthalmic compositions containing selective m1 muscarinic agonists for treating ocular hypertension |
JPWO2004069828A1 (ja) | 2003-02-04 | 2006-05-25 | 三菱ウェルファーマ株式会社 | ピペリジン化合物およびその医薬用途 |
US20050009817A1 (en) | 2003-04-30 | 2005-01-13 | Jennifer Savoy | Substituted heteroaryls |
US7652142B2 (en) | 2003-11-03 | 2010-01-26 | Schering Corporation | Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
MXPA06007054A (es) | 2003-12-19 | 2007-04-17 | Elixir Pharmaceuticals Inc | Metodos para tratar una enfermedad. |
WO2005060947A2 (en) | 2003-12-19 | 2005-07-07 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
JP2008501031A (ja) | 2004-05-28 | 2008-01-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
NZ553696A (en) | 2004-09-13 | 2010-02-26 | Ono Pharmaceutical Co | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
WO2006037052A2 (en) | 2004-09-27 | 2006-04-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Modulating mxa expression |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
WO2006130469A1 (en) | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
US8288413B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
-
2008
- 2008-09-08 US US12/205,968 patent/US8119661B2/en not_active Expired - Fee Related
- 2008-09-09 RU RU2010110036/04A patent/RU2010110036A/ru unknown
- 2008-09-09 AU AU2008299604A patent/AU2008299604A1/en not_active Abandoned
- 2008-09-09 EP EP08806636A patent/EP2197843B1/en not_active Not-in-force
- 2008-09-09 TW TW097134582A patent/TW200924766A/zh unknown
- 2008-09-09 KR KR1020107005282A patent/KR20100052528A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/GB2008/050802 patent/WO2009034380A1/en active Application Filing
- 2008-09-09 JP JP2010524582A patent/JP2010539151A/ja active Pending
- 2008-09-09 CA CA2699286A patent/CA2699286A1/en not_active Abandoned
- 2008-09-09 CN CN2008801155657A patent/CN101874020B/zh not_active Expired - Fee Related
- 2008-09-09 AT AT08806636T patent/ATE539056T1/de active
- 2008-09-09 BR BRPI0816331 patent/BRPI0816331A2/pt not_active Application Discontinuation
- 2008-09-09 ES ES08806636T patent/ES2377772T3/es active Active
- 2008-09-09 MX MX2010002584A patent/MX2010002584A/es not_active Application Discontinuation
- 2008-09-10 CL CL2008002689A patent/CL2008002689A1/es unknown
- 2008-09-10 UY UY31334A patent/UY31334A1/es unknown
- 2008-09-10 AR ARP080103926A patent/AR071245A1/es unknown
- 2008-09-11 PE PE2008001586A patent/PE20091090A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090076078A1 (en) | 2009-03-19 |
UY31334A1 (es) | 2009-04-30 |
EP2197843A1 (en) | 2010-06-23 |
WO2009034380A1 (en) | 2009-03-19 |
PE20091090A1 (es) | 2009-08-27 |
AU2008299604A1 (en) | 2009-03-19 |
CL2008002689A1 (es) | 2009-11-27 |
EP2197843B1 (en) | 2011-12-28 |
TW200924766A (en) | 2009-06-16 |
CA2699286A1 (en) | 2009-03-19 |
US8119661B2 (en) | 2012-02-21 |
MX2010002584A (es) | 2010-03-26 |
ATE539056T1 (de) | 2012-01-15 |
CN101874020B (zh) | 2012-11-07 |
JP2010539151A (ja) | 2010-12-16 |
KR20100052528A (ko) | 2010-05-19 |
BRPI0816331A2 (pt) | 2015-04-14 |
ES2377772T3 (es) | 2012-03-30 |
RU2010110036A (ru) | 2011-10-20 |
CN101874020A (zh) | 2010-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071245A1 (es) | Derivados de piperidina como antagonistas de receptores muscarinicos, procesos de obtencion y composiciones farmaceuticas | |
RU2395506C2 (ru) | Антагонисты рецептора хемокина | |
AR061306A1 (es) | Compuestos de pirrolidin-3-1l-piperidina como agonistas de receptores muscarinicos | |
AR060729A1 (es) | Compuestos agonistas de los receptores muscarinicos | |
AR061305A1 (es) | Agonistas de receptores muscarinicos | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR051952A1 (es) | Compuestos de n- sulfonilaminobencil - 2- fenoxicetamida sustituidos | |
PE20081837A1 (es) | Derivados de quinuclinidol como antagonistas de los receptores muscarinicos | |
HRP20140687T1 (hr) | Derivati benzofurana | |
AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
PE20070172A1 (es) | DERIVADOS BICICLICOS COMO INHIBIDORES DE p38 | |
JP2010539151A5 (es) | ||
AR078756A1 (es) | Moduladores alostericos positivos (map) | |
PE20091194A1 (es) | Derivados de heterociclicos como moduladores del receptor m1 | |
PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
PE20061362A1 (es) | Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion | |
HRP20150229T1 (hr) | Spojevi heteroarila kao ligandi receptora 5-ht4 | |
PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 | |
PE20091524A1 (es) | Derivados de 2-aminopirimidina | |
RU2007110482A (ru) | Композиции и способы для лечения когнитивных расстройств | |
PE20030718A1 (es) | Lactamas como antagonistas de taquiquininas | |
AR059018A1 (es) | Derivados de 6- fenil -1h- imidazo (4,5-c) piridina -4- carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina s y/o catepsina k | |
AR045819A1 (es) | Derivados de benzimidazol composiciones que los contienen, preparacion de los mismos y usos de los mismos | |
PE20061196A1 (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
PE20110206A1 (es) | Derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |